Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.

导出 OA

翻译打印收藏纠错

作者： Tommaso,Ceruti ^[1] ; Roberta,Frapolli ^[1] ; Carmen,Ghilardi ^[2] ; Alessandra,Decio ^[2] ; Giulia,Dellavedova ^[2] ; Sara,Tommasi ^[3] ; Massimo,Zucchetti ^[4] ; Arduino A,Mangoni ^[1]

作者单位： Laboratory of Cancer Pharmacology, Department of Oncology, Instituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. ^[1] Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Instituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy. ^[2] Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA 5042, Australia. ^[3] Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, SA 5042, Australia. ^[4]

关键词 DDAH1 inhibitors HPLC-MS/MS L-257 ZST316 dimethylarginine dimethylaminohydrolase 1 pharmacokinetics triple-negative breast cancer xenograft models

主题词人类(Humans);小鼠(Mice);动物(Animals);串联质谱法(Tandem Mass Spectrometry)

DOI 10.3390/molecules28248056

PMID 38138547

发布时间 2023-12-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交